Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer

Cancer Science

Volumn 99, Issue 12, 2008, Pages 2532-2539

  Horiuchi, Akiko ^a   Kikuchi, Norihiko ^a   Osada, Ryosuke ^a   Wang, Cuiju ^a   Hayashi, Akiko ^a   Nikaido, Toshio ^b   Konishi, Ikuo ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; EXOENZYME C3; MEVINOLIN; PRAVASTATIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PERITONEUM; RHOA GTP-BINDING PROTEIN; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57349135304     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00977.x     Document Type: Article

References (35)

1. Ozols RF, Rubin SC, Thomas GM et al. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott Williams & Wilkins, 2000: 981-1057.
2. Mutch DG, Williams S. Biology of epithelial ovarian cancer. Clin Obstet Gynecol 1994; 37: 406-22.
3. Imai T, Horiuchi A, Wang C et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 2003; 163: 1437-47.
4. Garofalo A, Naumova E, Manenti L et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 2003; 9: 3476-85.
5. Xu Y, Gaudette DC, Boynton JD et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995; 1: 1223-32.
6. Westermann AM, Havik E, Postma FR et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998; 9: 437-42.
7. Kikuchi N, Horiuchi A, Osada R et al. Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: An important autocrine/paracrine factor in tumor progression. Cancer Sci 2006; 97: 1061-9.
8. Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 1998; 12: 1589-98.
9. Kikuchi N, Horiuchi A, Imai T, Osada R, Konishi I. Nuclear expression of S100A4 protein is a maker for unfavorable outcomes in patients in patients with ovarian carcinoma. 11th Biennial Meeting of International Gynecologic Cancer Society. CA, USA: Santa Monica, 2006.
10. Horiuchi A, Kikuchi N, Imai T et al. Molecular target therapy in peritoneal dissemination of ovarian cancer. Jap J Gynecol Oncol 2005; 23: 234-8.
11. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res 2002; 84: 57-80.
12. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004; 265: 23-32.
13. Suwa H, Ohshio G, Imamura T et al. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998; 77: 147-52.
14. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999; 81: 682-7.
15. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60: 5832-8.
16. Kamai T, Arai K, Tsujii T, Honda M, Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 2001; 87: 227-31.
17. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. Characterization of RhoC expression in benign and malignant breast disease: A potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002; 160: 579-84.
18. Horiuchi A, Imai T, Wang C et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003; 83: 861-70.
19. Laufs and Liao. 2000 Fritz GHMG-CoA reductase inhibitors (statins) as anticancer drugs. Int J Oncol 2005; 27: 1401-9.
20. Yoshioka K, Matsumura F, Akedo H, Itoh K. Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J Biol Chem 1998; 273: 5146-54.
21. Albini A, Iwamoto Y, Kleinman HK et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45.
22. Plosker GL, Wagstaff AJ. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996; 51: 433-59.
23. Adamson P, Marshall CJ, Hall A, Tilbrook PA. Post-translational modifications of p21rho proteins. J Biol Chem 1992; 267: 20033-8.
24. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004; 4: 118-32.
25. Cáceres M, Guerrero J, Martínez J. Overexpression of RhoA-GTP induces activation of the epidermal growth factor receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells. Exp Cell Res 2005; 309: 229-38.
26. Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 2005; 15: 62-8.
27. Pillé JY, Denoyelle C, Varet J et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005; 11: 267-74.
28. Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-92.
29. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: A case-control study. Cancer 2004; 100: 2308-16.
30. Caruso MG, Osella AR, Notarnicola M et al. Prognostic value of low density lipoprotein receptor expression in colorectal carcinoma. Oncol Rep 1998; 5: 927-30.
31. Matar P, Matar P, Rozados VR, et al. Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 1999; 17: 19-25.
32. Zhong WB, Liang YC, Wang CY, Chang TC, Lee WS. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 2005; 12: 615-29.
33. Kusama T, Mukai M, Iwasaki T et al. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-17.
34. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998; 50: 83-93.
35. Knox JJ, Siu LL, Chen E et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005; 41: 523-30.